TY - JOUR
T1 - Implementation and early clinical results utilizing Cs-131 permanent interstitial implants for gynecologic malignancies
AU - Wooten, Charles Eric
AU - Randall, Marcus
AU - Edwards, Jason
AU - Aryal, Prakash
AU - Luo, Wei
AU - Feddock, Jonathan
N1 - Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2014/5
Y1 - 2014/5
N2 - Objective Permanent interstitial brachytherapy is an ideal yet underutilized treatment modality for accessible, small volume gynecological malignancies. We present early clinical results utilizing a new permanent isotope, Cs-131. Methods A retrospective review was performed evaluating patients treated with Cs-131 permanent interstitial radiation at our institution from July 2011 through June 2013. Doses were most commonly prescribed and calculated to a depth of 5 mm using Paterson-Parker planar implant rules for Au-198. This activity was converted to air-kerma strength (U). A conversion factor of 1.1 was applied based on RBE calculations, clinical observation and experience. Results 14 patients were identified among whom 17 Cs-131 implants were performed. Seven patients were implanted as sole therapy, and a median dose of 50 Gy was delivered. Ten implants were performed as boost within a more extensive radiation treatment plan. In these patients, a median implant dose of 27.5 Gy was used and the median total dose delivered in combination was 78.25 Gy. After a median follow up of 12 months, the actuarial local control rate was 84.4%. A very low level of grade 1-3 reactions was observed with no fistula formations or other severe side effects. Conclusions Permanent interstitial brachytherapy with Cs-131 was well tolerated with favorable early results compared to other series. Cs-131 has multiple favorable properties, including minimal radiation exposure to treating staff, and should be considered as a therapeutic option in appropriately selected patients. A methodology for dose prescription, calculation of radioactivity required and distribution of the isotope is also presented.
AB - Objective Permanent interstitial brachytherapy is an ideal yet underutilized treatment modality for accessible, small volume gynecological malignancies. We present early clinical results utilizing a new permanent isotope, Cs-131. Methods A retrospective review was performed evaluating patients treated with Cs-131 permanent interstitial radiation at our institution from July 2011 through June 2013. Doses were most commonly prescribed and calculated to a depth of 5 mm using Paterson-Parker planar implant rules for Au-198. This activity was converted to air-kerma strength (U). A conversion factor of 1.1 was applied based on RBE calculations, clinical observation and experience. Results 14 patients were identified among whom 17 Cs-131 implants were performed. Seven patients were implanted as sole therapy, and a median dose of 50 Gy was delivered. Ten implants were performed as boost within a more extensive radiation treatment plan. In these patients, a median implant dose of 27.5 Gy was used and the median total dose delivered in combination was 78.25 Gy. After a median follow up of 12 months, the actuarial local control rate was 84.4%. A very low level of grade 1-3 reactions was observed with no fistula formations or other severe side effects. Conclusions Permanent interstitial brachytherapy with Cs-131 was well tolerated with favorable early results compared to other series. Cs-131 has multiple favorable properties, including minimal radiation exposure to treating staff, and should be considered as a therapeutic option in appropriately selected patients. A methodology for dose prescription, calculation of radioactivity required and distribution of the isotope is also presented.
KW - Brachytherapy
KW - Cs-131
KW - Gynecologic cancer
KW - Interstitial radiation
KW - Radiation implant
KW - Re-irradiation
UR - http://www.scopus.com/inward/record.url?scp=84899655514&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899655514&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2014.02.015
DO - 10.1016/j.ygyno.2014.02.015
M3 - Article
C2 - 24556059
AN - SCOPUS:84899655514
SN - 0090-8258
VL - 133
SP - 268
EP - 273
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 2
ER -